Incyte Corporation (INCY) AI Stock Analysis

Incyte Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics across hematology/oncology, inflammation, and autoimmunity. Its key commercial products include JAKAFI for intermediate or high-risk myelofibrosis, MONJUVI/MINJUVI for relapsed or refractory diffuse large B-cell lymphoma, PEMAZYRE for liquid and solid tumors, and ICLUSIG for leukemia indications. The company's pipeline includes candidates such as axatilimab for chronic GVHD and parsaclisib in Phase II trials for lymphomas. Headquartered in Wilmington, Delaware, Incyte maintains strategic collaborations with pharmaceutical leaders including Novartis, Lilly, and Merus to advance its pipeline globally.

Incyte expanded its revenue from $2.99B in FY2021 to $5.14B in FY2025, reflecting a 5-year revenue CAGR of 14.0%. Net income rose to $1.29B in FY2025, up from $32.6M in FY2024 and $948.6M in FY2021. Gross margin remained high at 92.8% in FY2025, while operating margin recovered to 26.1% from 2.4% in FY2024, when R&D expense peaked at $2.61B. For the trailing twelve months ended June 30, 2026, revenue stood at $5.82B with a profit margin of 27.7%. In the latest quarter ended June 30, 2026, quarterly revenue grew 37.7% year-over-year, matching a quarterly earnings growth rate of 37.7%.

As of June 30, 2026, Incyte held $4.54B in cash and short-term investments against total debt of $38.3M, yielding a net cash position of $4.50B. Its current ratio stood at 4.66 and debt-to-equity was 0.01. Free cash flow reached $1.35B in FY2025, up from operating cash flow of $1.41B. Capital expenditures were $58.9M in FY2025, while share buybacks totaled $19.1M, alongside a 5-year share count change of -6.2%.

Incyte trades at a trailing P/E of 14.4x and a forward P/E of 14.7x, both below the median of its S&P 500 Healthcare peers at 28.9x and 16.6x, respectively. Its enterprise value to EBITDA multiple of 10.3x also sits below the peer median of 15.7x, while its price-to-sales ratio of 3.9x compares to the peer median of 3.4x. Over the past year, the stock returned 29.5%, outperforming the S&P 500 (SPY) return of 16.8%, though its 5-year return of 72.5% trailed the index return of 83.0%.

Wall Street analysts maintain 10 Strong Buy, 2 Buy, 15 Hold, and 1 Sell recommendations on Incyte. The mean price target is $129.50, representing an upside of 14.5% from the last close of $113.07 on October 16, 2026. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $5.94B and EPS of $3.12. Incyte beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is October 29, 2026.

This page is an AI-written research summary of Incyte Corporation (INCY). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: INCY income statement, INCY balance sheet, INCY key metrics, INCY analyst forecast, INCY chart. See the INCY stock overview for the latest quote and news.